Drugs / Aclerastide
Aclerastide
also known as
DSC127 · NorLeu(3)-A(1-7) · \[Nle3\]-Angiotensin II (1-7) · Aclerastida · Asp-arg-nle-tyr-ile-his-pro · Norleu3-angiotensin(1-7) · USB-001 · USB-005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03615196 | Jul → Nov 2018 | — | US Biotest, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01840085 | Dec 2015 | ulcer of lower limbs | Integra LifeSciences Corporation | Terminated | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00796744 Comparator | Oct 2008 → Dec 2010 | chronic ulcer of skin | US Biotest, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01849965 Comparator | Apr 2013 → Dec 2015 | ulcer of lower limbs | Integra LifeSciences Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01830348 Comparator | Feb 2013 → Dec 2015 | ulcer of lower limbs | Integra LifeSciences Corporation | Terminated | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aclerastide | “To determine if aclerastide (DSC127) is effective in increasing incidence of complete wound closure up to 10 weeks confirmed 2 weeks later, compared with vehicle” NCT01849965 ↗ |
| Known as | \[Nle3\]-Angiotensin II (1-7) | “Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration.” NCT03615196 ↗ |
| Known as | Aclerastida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297940 ↗ |
| Known as | Asp-arg-nle-tyr-ile-his-pro | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297940 ↗ |
| Known as | DSC127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01849965 ↗ |
| Known as | NorLeu(3)-A(1-7) | “This randomized, double-blind, placebo-controlled Phase 2 clinical trial explored NorLeu(3)-A(1-7) (DSC127) safety and healing efficacy in diabetic foot ulcers.” PMID 22672145 ↗ Jun 2012 |
| Known as | Norleu3-angiotensin(1-7) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297940 ↗ |
| Known as | USB-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297940 ↗ |
| Known as | USB-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297940 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297940 ↗ |
| Route | Topical | “daily topical application” NCT01830348 ↗ |